TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31531828

Group type: EXPERIMENTAL
Intervention: Perioperative multi-system optimization protocol
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 127
Study: 30073273

Group type: EXPERIMENTAL
Intervention: Peer comparison letters
Number of subjects: 5055
Study: 27118212

Group type: EXPERIMENTAL
Intervention: Intramuscular paracetamol (600 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Oral syrup paracetamol (600 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intramuscular or oral syrup paracetamol (1000 mg administered six-hourly)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Loading dose of 1500 mg followed by 1000 mg maintenance dose
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Paracetamol concentrations
Number of subjects: 21
Study: 25018116

Group type: EXPERIMENTAL
Intervention: CYD dengue vaccine (three injections at months 0, 6, and 12)
Number of subjects: 10275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10275

Group type: EXPERIMENTAL
Intervention: CYD dengue vaccine
Number of subjects: 10275
Study: 22198447

Group type: EXPERIMENTAL
Intervention: Augmentation (N = 269)
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Switching (N = 269)
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Augmentation
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Switching
Number of subjects: 1292
Study: 20085937

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with carboplatin and paclitaxel (PCB) with high blood pressure (HBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with carboplatin and paclitaxel (PCB) without high blood pressure (HBP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypertension incidence
Number of subjects: 0
Study: 18574759

Group type: EXPERIMENTAL
Intervention: Hirayama's disease patients in neutral position
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Hirayama's disease patients in flexed position
Number of subjects: 56

Group type: COMPARATOR
Intervention: Healthy controls in neutral position
Number of subjects: 56

Group type: COMPARATOR
Intervention: Healthy controls in flexed position
Number of subjects: 56
Study: 15983245

Group type: EXPERIMENTAL
Intervention: N-terminal-proBNP (NT-proBNP)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Renin
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: NT-proBNP and Renin (both in highest quarters)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: NT-proBNP and Renin (after adjustment for other predictors)
Number of subjects: 206

Group type: COMPARATOR
Intervention: C (Control group)
Number of subjects: 206
Study: 12521403

Group type: EXPERIMENTAL
Intervention: Nicotine 2-mg sublingual tablet (n = 120)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Placebo (n = 121)
Number of subjects: 241
Study: 10604733

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg or 800 mg twice a day)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study: 7866815

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily for 12 weeks, followed by a maximum of four 5 mg tablets (20 mg max daily) for 12 weeks
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily for 6 weeks, then 10 mg for 6 weeks
Number of subjects: 119
Study: 1772923

Group type: EXPERIMENTAL
Intervention: HU-PACS (CRT monitor)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CR film
Number of subjects: 20
Study: 6127501

Group type: EXPERIMENTAL
Intervention: Aluminium toxicity
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vitamin-D therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dialysis fluid
Number of subjects: 16
Study: 31220015

Group type: EXPERIMENTAL
Intervention: Functional strength and power training
Number of subjects: 30
Study: 29101134

Group type: EXPERIMENTAL
Intervention: Steam inhalation for recurrent sinusitis
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nasal irrigation
Number of subjects: 32
Study: 27383762

Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg once daily (QD)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg once daily (QD)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 26030947

Group type: EXPERIMENTAL
Intervention: Translabial three-dimensional sonography (3D USG)
Number of subjects: 100
Study: 22822929

Group type: EXPERIMENTAL
Intervention: Johnson's Baby Skincare fragrance free wipe
Number of subjects: 280

Group type: COMPARATOR
Intervention: Cotton wool and water
Number of subjects: 280
Study: 18180760

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic drugs
Number of subjects: 7323

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 7323
Study: 17855466

Group type: EXPERIMENTAL
Intervention: Nurse case-managed intervention
Number of subjects: 295

Group type: COMPARATOR
Intervention: Standard care control program
Number of subjects: 295
Study: 15776065

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (specific drug not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy (not specified)
Number of subjects: 0
Study: 11957789

Group type: EXPERIMENTAL
Intervention: Antioxidative therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antioxidative vitamins (tocopherol)
Number of subjects: 0
Study: 10335929

Group type: EXPERIMENTAL
Intervention: Italian version of the Hospital Anxiety and Depression Scale (HADS) administered before chemotherapy and at follow-up.
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Receiver operating characteristics (ROC) analysis for HADS.
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: 14-item total scale of HADS.
Number of subjects: 197
Study: 8635777

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) with amino acid based glucose electrolyte solution (Vamin) and lipid emulsion (Intralipid)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Conventional intravenous dextrose with or without electrolytes plus enteral milk regimen
Number of subjects: 85
Study: 2035442

Group type: EXPERIMENTAL
Intervention: Molsidomine (4 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nifedipine (10 mg)
Number of subjects: 12
Study: 7044535

Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU), cyclophosphamide, and prednisone (BCP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Melphalan (Alkeran) and prednisone (AP)
Number of subjects: 0
Study: 29288402

Group type: EXPERIMENTAL
Intervention: Intensive prevention in kindergarten with fluoride gel at school
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive prevention in kindergarten without fluoride gel at school
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic prevention in kindergarten with fluoride gel at school
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic prevention in kindergarten without fluoride gel at school
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No organized prevention in kindergarten with fluoride gel at school
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No organized prevention in kindergarten without fluoride gel at school
Number of subjects: 0
Study: 27859680

Group type: EXPERIMENTAL
Intervention: Teaching Recovery Techniques (TRT) intervention
Number of subjects: 482

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 482
Study: 25047245

Group type: EXPERIMENTAL
Intervention: Problem-Solving Treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 120
Study: 22849403

Group type: EXPERIMENTAL
Intervention: Increased activation in the right pars triangularis during fMRI tasks in older adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right pars orbitalis activation during the word task in older adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Behavioral performance in fMRI task
Number of subjects: 0
Study: 19615826

Group type: EXPERIMENTAL
Intervention: Micronized E(2) 1mg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 18685050

Group type: EXPERIMENTAL
Intervention: Platelet gel
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 35
Study: 16794387

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Conventional Nissen fundoplication (CNF)
Number of subjects: 177
Study: 12571296

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 514

Group type: COMPARATOR
Intervention: Nonresurfacing of the patella
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Secondary resurfacing
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Bilateral knee replacement with resurfacing
Number of subjects: 514
Study: 11070746

Group type: EXPERIMENTAL
Intervention: Zafirlukast ('Accolate') 20 mg twice daily
Number of subjects: 60
Study: 8889482

Group type: EXPERIMENTAL
Intervention: Hypotonic glucose‐electrolyte solution (H: 90 mmol/l glucose; 60 mmol/l Na+; 240 mosmol/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isotonic glucose‐electrolyte solution (I: 200 mmol/l glucose; 35 mmol/l Na+; 310 mosmol/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 12

Group type: COMPARATOR
Intervention: No drink
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hypotonic glucose‐electrolyte solution (H)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 12
Study: 1987957

Group type: EXPERIMENTAL
Intervention: Pulsed Doppler ultrasound monitoring of blood velocity in the fetal aorta and umbilical artery
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Umbilical artery examination
Number of subjects: 139
Study: 6297202

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (dexamethasone 2.0 mg/day for 3 days)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Withdrawal of glucocorticoid substitution therapy for 84 hours
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exogenous ACTH1-24 administration
Number of subjects: 6
Study: 30842160

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Patients with breast cancer
Number of subjects: 86

Group type: COMPARATOR
Intervention: Healthy female blood donors (control cohort)
Number of subjects: 86
Study: 28438238

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 42
Study: 25730788

Group type: EXPERIMENTAL
Intervention: Cranoff (Test drug) 500mg, two capsules, prescribed for 2-3 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Urixin (Control drug) 400mg capsules, prescribed for 2-3 weeks
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Cranoff (Test drug)
Number of subjects: 130
Study: 23749615

Group type: EXPERIMENTAL
Intervention: Occupation-related rehabilitation program (IG)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 309
Study: 21087403

Group type: EXPERIMENTAL
Intervention: NGX-4010 (8% capsaicin dermal patch, 640 µg/cm²)
Number of subjects: 418

Group type: COMPARATOR
Intervention: 0.04% capsaicin control patch (3.2 µg/cm²)
Number of subjects: 418
Study: 20029098

Group type: EXPERIMENTAL
Intervention: Resistance-training group (5-kg medicine ball, 2 sets of 8 reps per session)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Velocity-training group (regular soccer ball, 4 sets of 16 reps per session)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (5-kg medicine ball)
Number of subjects: 64
Study: 17161760

Group type: EXPERIMENTAL
Intervention: PREHAB - individualized program focusing on impairments (standardly tailored design)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: DRIVER - entire intervention (global design)
Number of subjects: 366
Study: 14748023

Group type: EXPERIMENTAL
Intervention: Surgery with x 2.5 magnification and microsurgical instruments (Group A)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Surgery with no magnification (Group B)
Number of subjects: 97
Study: 11577259

Group type: EXPERIMENTAL
Intervention: Tirofiban/heparin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 110
Study: 9570601

Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia Block (SAB)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined Sciatic and Femoral Block (SFB)
Number of subjects: 39
Study: 7804511

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 3392220

Group type: EXPERIMENTAL
Intervention: Induction of worry
Number of subjects: 128

Group type: COMPARATOR
Intervention: Other conditions (depressed, somatically anxious, neutral)
Number of subjects: 128
Study: 31471115

Group type: EXPERIMENTAL
Intervention: Milking of umbilical cord blood
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed clamping of umbilical cord blood
Number of subjects: 0
Study: 31036040

Group type: EXPERIMENTAL
Intervention: ATRA + oxaliplatin + 5-fluorouracil/leucovorin (FOLFOX4)
Number of subjects: 368

Group type: COMPARATOR
Intervention: FOLFOX4 alone
Number of subjects: 368
Study: 28623938

Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 26041459

Group type: EXPERIMENTAL
Intervention: DASH diet and increased walking
Number of subjects: 40

Group type: COMPARATOR
Intervention: American Diabetes Association diet
Number of subjects: 40
Study: 22963833

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy for 24-38 weeks
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 527
Study: 21045817

Group type: EXPERIMENTAL
Intervention: Hemp Seed Pill (HSP) 7.5 g b.i.d.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 19661478

Group type: EXPERIMENTAL
Intervention: Brief psychosocial-behavioral intervention plus antidepressant
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care including antidepressant
Number of subjects: 101
Study: 16707901

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape obturator (TVT-O)
Number of subjects: 89
Study: 15114207

Group type: EXPERIMENTAL
Intervention: 4 ml/kg NaCl, 7.5%
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 4 ml/kg NaCl, 0.9%
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 32 ml/kg NaCl, 0.9%
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study: 11556267

Group type: EXPERIMENTAL
Intervention: Pen-switching method
Number of subjects: 100

Group type: COMPARATOR
Intervention: Flowchart method
Number of subjects: 100
Study: 9631218

Group type: EXPERIMENTAL
Intervention: Exercise challenge test (ECT) in subzero temperature during winter
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Exercise challenge test (ECT) at the end of the birch pollen season in summer
Number of subjects: 58

Group type: COMPARATOR
Intervention: Subgroup of 19 non-atopic symptom-free runners
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both winter and pollen season ECT
Number of subjects: 58
Study: 8161001

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 286

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 286
Study: 3123619

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 30131565

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (7 mg/24 h)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 27798210

Group type: EXPERIMENTAL
Intervention: 800 mg intravenous solithromycin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 400 mg oral moxifloxacin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 26139388

Group type: EXPERIMENTAL
Intervention: Blended learning with Web-based virtual patients (VPs) and standard PBLS training
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard PBLS training (control group)
Number of subjects: 57
Study: 24432626

Group type: EXPERIMENTAL
Intervention: Qilin Pills + levofloxacin
Number of subjects: 80

Group type: COMPARATOR
Intervention: levofloxacin
Number of subjects: 80
Study: 21668635

Group type: EXPERIMENTAL
Intervention: SRL + TAC (week 13 TAC elimination)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: SRL + MMF
Number of subjects: 443

Group type: COMPARATOR
Intervention: TAC + MMF
Number of subjects: 443
Study: 18316457

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba treatment for mild-moderate dementia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mini Mental State examination
Number of subjects: 0
Study: 17047215

Group type: EXPERIMENTAL
Intervention: Preoperative inspiratory muscle training (IMT)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 279
Study: 12726868

Group type: EXPERIMENTAL
Intervention: Educational intervention (three-hour sessions targeting PPE use)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 400
Study: 11584255

Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Heated humidifying system (HHS)
Number of subjects: 243
Study: 9604126

Group type: EXPERIMENTAL
Intervention: Rufinamide 600 mg after overnight fasting
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rufinamide 600 mg after a fat and protein rich breakfast
Number of subjects: 12
Study: 7973238

Group type: EXPERIMENTAL
Intervention: Statistical model for a repeated measures clinical trial with proliferative index data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot randomized clinical trial
Number of subjects: 0
Study: 2513931

Group type: EXPERIMENTAL
Intervention: Needle aspiration + Metronidazole 2.4 g/day for 10 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Metronidazole 2.4 g/day for 10 days
Number of subjects: 39
Study: 1092444

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic therapy initiated preoperatively, with moderately high dosage for short periods.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical technique
Number of subjects: 0
Study: 30999260

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) monotherapy, starting dose 1600 mg QD (or 1200 mg if previously reduced), adjustable between 800–2400 mg QD.
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) monotherapy
Number of subjects: 274
Study: 28253839

Group type: EXPERIMENTAL
Intervention: Integrated CKD Care
Number of subjects: 442

Group type: COMPARATOR
Intervention: Control group (standard treatments)
Number of subjects: 442
Study: 25227704

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 23266241

Group type: EXPERIMENTAL
Intervention: High vibration (45Hz, 5mm)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low vibration (30Hz, 5mm)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No vibration
Number of subjects: 11
Study: 21897336

Group type: EXPERIMENTAL
Intervention: Ethyl alcohol-intoxicated patients (mean ethyl alcohol, 251 [SD, 87] mg/dL)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (sober and healthy)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Alcohol infusions combined with initial oral alcohol load up to a blood alcohol steady state of 100 mg/dL (healthy volunteers, n = 12)
Number of subjects: 121
Study: 18452779

Group type: EXPERIMENTAL
Intervention: Fluvastatin 30 mg/day plus conventional calcium-channel blocker (CCB) therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional calcium-channel blocker (CCB) therapy
Number of subjects: 64
Study: 16492692

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/d) for 36 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 22
Study: 12953799

Group type: EXPERIMENTAL
Intervention: Low sodium intake with adequate calcium and magnesium
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Low sodium intake
Number of subjects: 6
Study: 10848662

Group type: EXPERIMENTAL
Intervention: Alosetron (2 mg b.d. administered orally)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 9095005

Group type: EXPERIMENTAL
Intervention: Risk classification system based on historical and ECG factors
Number of subjects: 626

Group type: COMPARATOR
Intervention: No risk factors
Number of subjects: 626
Study: 8466367

Group type: EXPERIMENTAL
Intervention: Cefotaxime 4 g/day for 21 days plus aminoglycoside for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional medical management (beta lactam plus aminoglycoside for 21 to 50 days)
Number of subjects: 20
Study: 31429944

Group type: EXPERIMENTAL
Intervention: Pain condition (painful stimuli)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No pain condition (nonpainful stimuli)
Number of subjects: 30
Study: 30829308

Group type: EXPERIMENTAL
Intervention: Tunica vaginalis (TV) flap
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preputial dartos (PD) fascia
Number of subjects: 0
Study: 29905456

Group type: EXPERIMENTAL
Intervention: Eye makeup remover with Ocusoft®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eye makeup remover with water
Number of subjects: 0
Study: 25240454

Group type: EXPERIMENTAL
Intervention: Abnormal MPS
Number of subjects: 400

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Invasive-medical strategy
Number of subjects: 400
Study: 22704412

Group type: EXPERIMENTAL
Intervention: salvianolate combined with alprostadil and reduced glutathione liquid intravenously for 7 to 10 days, repeated monthly for four years
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapy with the same oral medicines
Number of subjects: 30